Discussions by the Ministry of Health, Labor and Welfare’s (MHLW) study group on the generic industry structure are reaching the last lap. Its final report - a draft of which will be presented later this month - is expected to…
HOME > LATEST
LATEST
-
ARCHIVE FY2003 Social Security-related Budget Request Up \691 Bil.
August 26, 2002
-
ARCHIVE OTC NEWS IN BRIEF
August 26, 2002
-
ARCHIVE MCC to Review Disadvantages of Split-off Policy
August 19, 2002
-
ARCHIVE Record-high Life Expectancy Reported for Both Sexes in 2001
August 19, 2002
-
ARCHIVE FPMAJ to Present Industry's Proposal Regarding Application of New PAL
August 19, 2002
-
ARCHIVE Drugs to Be Included in 20th Quality Reevaluation Announced
August 19, 2002
-
ARCHIVE Fujisawa Invests US$8 Mil. in Sucampo
August 19, 2002
-
ARCHIVE REGULATORY NEWS IN BRIEF
August 19, 2002
-
ARCHIVE Tanabe to Establish JV with aaiPharma
August 19, 2002
-
ARCHIVE MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
August 19, 2002
-
ARCHIVE Gedeon Richter Sues 12 GE Houses for Famotidine Patent Infringement
August 19, 2002
-
ARCHIVE New Therapeutic GL for Arteriosclerotic Diseases Published
August 19, 2002
-
ARCHIVE ACNielsen, So-net M3 to Start Market Survey Service via MR-kun
August 19, 2002
-
ARCHIVE Shionogi to Collaborate with Oncotherapy Science for Genome-based Drug Discovery
August 19, 2002
-
ARCHIVE Chronic Heart Failure as Additional Indication Approved for Daiichi's Carvedilol
August 19, 2002
-
ARCHIVE Nippon Kayaku Developing DDS for Anticancer Drugs
August 19, 2002
-
ARCHIVE Toho Prepared for End Deals if Accord Not to Be Reached on Prices
August 19, 2002
-
ARCHIVE PRESS SEMINAR
August 19, 2002
-
ARCHIVE Ca Antagonists to Coexist with AII Antagonists
August 19, 2002
-
ARCHIVE Terumo's Hepaflush Prefilled Syringes Selling Well
August 19, 2002
ページ
Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…